Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCWB HCW Biologics	$5.50 +5.4%	$7.66	$5.00 ▼ $100.80	$7.91M	0.83	262,540 shs	54,567 shs
LVTX LAVA Therapeutics	$1.31 -2.2%	$1.27	$0.85 ▼ $2.52	$34.46M	0.48	158,036 shs	1,848 shs
SCYX SCYNEXIS	$0.82 -6.6%	$0.90	$0.72 ▼ $2.29	$32.07M	1.65	162,437 shs	140,592 shs
TPST Tempest Therapeutics	$7.11 -4.8%	$6.98	$5.35 ▼ $40.56	$26.18M	-2	174,174 shs	132,227 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCWB HCW Biologics	-4.92%	-14.98%	+0.19%	-60.97%	-87.80%
LVTX LAVA Therapeutics	-2.19%	+3.88%	+4.78%	+0.75%	-42.24%
SCYX SCYNEXIS	+0.29%	-5.79%	-8.64%	+3.06%	-59.97%
TPST Tempest Therapeutics	-15.88%	+8.42%	+8.73%	-31.10%	-81.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCWB HCW Biologics	3.5701 of 5 stars	3.5	5.0	3.4	3.3	0.0
LVTX LAVA Therapeutics	2.4986 of 5 stars	3.0	5.0	3.0	0.0	0.6
SCYX SCYNEXIS	0.9081 of 5 stars	0.0	2.0	4.1	0.8	0.6
TPST Tempest Therapeutics	2.5403 of 5 stars	3.3	5.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCWB HCW Biologics	3.00	Buy	$35.00	536.36% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	141.73% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	321.94% Upside

Current Analyst Ratings Breakdown

Latest HCWB, LVTX, SCYX, and TPST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	HCWB HCW Biologics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$120.00 ➝ $35.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
4/10/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$16.00 ➝ $16.00
4/10/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Perform	$7.00 ➝ $9.00
3/31/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.50
3/28/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$169.00 ➝ $91.00
3/28/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$611.00 ➝ $208.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCWB HCW Biologics	$1.45M	5.48	N/A	N/A	$0.37 per share	14.86
LVTX LAVA Therapeutics	$4.99M	6.91	N/A	N/A	$1.95 per share	0.67
SCYX SCYNEXIS	$2.63M	12.20	$1.42 per share	0.58	$1.96 per share	0.42
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCWB HCW Biologics	-$24.99M	-$23.25	N/A	∞	N/A	-1,067.82%	-2,516.84%	-132.95%	N/A
LVTX LAVA Therapeutics	-$41.97M	-$1.04	N/A	N/A	N/A	N/A	-62.22%	-29.37%	8/19/2025 (Estimated)
SCYX SCYNEXIS	$67.04M	-$0.56	N/A	16.44	N/A	-425.41%	-66.21%	-38.84%	8/6/2025 (Estimated)
TPST Tempest Therapeutics	-$29.49M	-$17.98	N/A	N/A	N/A	N/A	-187.44%	-82.61%	8/6/2025 (Estimated)

Latest HCWB, LVTX, SCYX, and TPST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	HCWB HCW Biologics	N/A	-$0.05	N/A	-$0.05	N/A	N/A
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/13/2025	Q1 2025	TPST Tempest Therapeutics	-$3.71	-$3.16	+$0.55	-$3.16	N/A	N/A
3/28/2025	Q4 2024	HCWB HCW Biologics	N/A	-$3.20	N/A	-$0.08	N/A	$0.40 million
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million
3/27/2025	Q4 2024	TPST Tempest Therapeutics	-$3.12	-$4.03	-$0.91	-$0.31	N/A	$0.49 million
3/12/2025	Q4 2024	SCYX SCYNEXIS	-$0.22	-$0.09	+$0.13	-$0.09	N/A	$0.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCWB HCW Biologics	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCWB HCW Biologics	N/A	0.07	0.07
LVTX LAVA Therapeutics	N/A	5.36	5.36
SCYX SCYNEXIS	N/A	3.13	3.13
TPST Tempest Therapeutics	N/A	1.69	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCWB HCW Biologics	2.96%
LVTX LAVA Therapeutics	N/A
SCYX SCYNEXIS	54.37%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
HCWB HCW Biologics	42.70%
LVTX LAVA Therapeutics	9.50%
SCYX SCYNEXIS	4.86%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCWB HCW Biologics	40	1.44 million	22.32 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	26.08 million	Optionable
SCYX SCYNEXIS	60	39.02 million	36.87 million	Optionable
TPST Tempest Therapeutics	20	3.68 million	41.59 million	Optionable

HCWB, LVTX, SCYX, and TPST Headlines

Recent News About These Companies

Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%

June 11 at 3:54 PM | msn.com

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock

June 11 at 8:27 AM | quiverquant.com

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11 at 8:00 AM | globenewswire.com

Tempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic Alternatives

June 7, 2025 | marketwatch.com

Tempest Therapeutics Shares Up, Executive Team Enters Into Consulting Agreements

June 7, 2025 | marketwatch.com

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

June 6, 2025 | zacks.com

Tempest Therapeutics stock rises on EMA Orphan Drug Designation

June 5, 2025 | au.investing.com

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 5, 2025 | globenewswire.com

Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finance.yahoo.com

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 28, 2025 | globenewswire.com

Dual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

April 25, 2025 | empr.com

Cash-strapped Bay Area biotech company lays off all but 5 employees

April 24, 2025 | msn.com

Tempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495

April 23, 2025 | nasdaq.com

Tempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous Polyposis

April 23, 2025 | nasdaq.com

Tempest Therapeutics

April 22, 2025 | thepharmaletter.com

Tempest Therapeutics stock rises on FDA Orphan Drug Designation

April 21, 2025 | in.investing.com

Tempest lays off 80% of workforce to ride out cash crunch

April 21, 2025 | fiercebiotech.com

Tempest Therapeutics announces FDA granted ODD to TPST-1495

April 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB, LVTX, SCYX, and TPST Company Descriptions

HCW Biologics NASDAQ:HCWB

$5.50 +0.28 (+5.36%)

As of 04:00 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

LAVA Therapeutics NASDAQ:LVTX

$1.31 -0.03 (-2.24%)

As of 03:50 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

SCYNEXIS NASDAQ:SCYX

$0.82 -0.06 (-6.59%)

As of 04:00 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Tempest Therapeutics NASDAQ:TPST

$7.11 -0.36 (-4.82%)

As of 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time